COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI HC QHC Q BHBH CICI BLBL NZNZ COCO BUBU More..
Proxalutamide study #3 of 3
3/10 Late treatment study
Cadegiani et al., Press Conference (Preprint)
The Proxa-Rescue AndroCoV Trial
Source   PDF   Share   Tweet
RCT 590 hospitalized patients, 294 treated with proxalutamide showing significantly lower mortality and faster recovery.

Cadegiani et al., 3/10/2021, Double Blind Randomized Controlled Trial, Brazil, South America, preprint, baseline oxygen requirements 97.0%, 5 authors.
risk of death, 91.4% lower, RR 0.09, p < 0.001, treatment 12 of 294 (4.1%), control 141 of 296 (47.6%).
risk of mechanical ventilation, 91.6% lower, RR 0.08, p < 0.001, treatment 13 of 294 (4.4%), control 156 of 296 (52.7%).
recovery time, 84.2% lower, relative time 0.16, treatment 294, control 296.
hospitalization time, 64.3% lower, relative time 0.36, treatment 294, control 296.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 3 studies
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation.
Submit